Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7912): 172-179, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545680
3.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33577729
4.
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
J Pathol
; 261(3): 349-360, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667855
5.
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Future Oncol
; 20(7): 351-360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994649
6.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature
; 554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29443960
7.
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7914): E5, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641605
8.
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
Proc Natl Acad Sci U S A
; 117(22): 12288-12294, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430334
9.
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Oncologist
; 27(3): e223-e232, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274723
10.
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
BJU Int
; 129(4): 463-469, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866683
11.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
12.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560
13.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 124(7): 1214-1221, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473164
14.
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
J Urol
; 205(2): 414-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32935617
15.
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia.
Adv Anat Pathol
; 28(4): 179-195, 2021 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128483
16.
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.
Adv Anat Pathol
; 28(4): 196-208, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128484
17.
Dermatologic infections in cancer patients treated with checkpoint inhibitors.
J Am Acad Dermatol
; 85(6): 1528-1536, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744355
18.
Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.
Dig Dis Sci
; 66(2): 537-540, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32185662
19.
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer
; 126(11): 2597-2606, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208524
20.
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Cancer
; 126(20): 4532-4544, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767682